Turing Pharmaceuticals CEO Martin Shkreli confirmed that the price of Daraprim will go down by the end of the year, but it will only be a “modest” decrease.
A New York Times article reported that a price decrease for Daraprim would be on the order of 10%. But Shkreli told Business Insider that that number was taken out of context.
He had said there would be a modest decrease, and was then asked what “modest” would be for him. That, he said, is where the 10% came in, but there’s no decision just yet.
“We’ll announce when we announce,” he said.
He added that the announcement will come by December 25, though he added that he’s not constantly thinking about it.
Shkreli also added that Valeant Pharmaceuticals and other companies that practice what Democratic presidential candidate Hillary Clinton and others have labelled “price gouging” still haven’t lowered the prices on any of their drugs.
“Nobody’s lowered their prices … why should I?” he said.
“When my lawyers tell me I absolutely have to go, I’ll go,” he said. “They don’t have subpoena power until they have got widespread support. I don’t have to go to a hearing unless there’s widespread support.”
NOW WATCH: Briefing videos
Business Insider Emails & Alerts
Site highlights each day to your inbox.